FB 1006
Alternative Names: FB-1006Latest Information Update: 03 Nov 2022
Price :
$50 *
At a glance
- Originator 4B Technologies; Peking University
- Developer 4B Technologies
- Class Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 09 Sep 2022 Preclinical trials in Amyotrophic lateral sclerosis in China (unspecified route) (4B Technologies pipeline, September 2022)
- 09 Mar 2022 4B Technologies and Peking University entered into strategic collaboration to co-develop therapeutic solutions for Amyotrophic lateral sclerosis
- 07 Sep 2021 4B Technologies enters into partnership with Insilico Medicine for Insilico’s AI software for research and development workflow